Current News

Contact | Print version | PDF version | Send article | RSS feed

Cryptome Discovers Novel Compounds to Treat Cancer

02 Aug 2005 - Cryptome Pharmaceuticals Ltd announced that it has lodged a provisional patent application on a broad class of compounds to treat cancer. The compounds have been shown to inhibit growth of cancer cells and to inhibit angiogenesis in the laboratory. They were discovered using the company's proprietary "Cryptomics" platform.
 
This class of compound has already been filed for anticoagulant properties. Cryptome will be investigating these molecules to select one or more lead candidates and then will proceed to determine efficacy in relevant disease animal models. Further details of the clinical potential in cancer and the molecular basis of these compounds will be released as the results of this work become available.
 
Cryptome's Chief Scientific Officer, Dr Vic Ilag noted, "The invention once again covers a broad and novel class of compounds and not a single molecule. Our team were able to produce this result in less than a year from the time we initiated our cancer drug discovery programme. This is much quicker than the 3 years or more for conventional discovery programmes starting from target identification".